Academic medical centers write their own rules  by Freischlag, Julie Ann
Academic medical centers write their own rules
Julie Ann Freischlag, MD, Baltimore, Md
The interaction between pharmaceutical and device companies and hospitals and physicians has undergone significant
transformation in the past few years due to the public’s perception that bias may result when such relationships are not
disclosed and monitored. Policies need to be written by medical centers and hospitals to preserve and retain the trust of
the public. The policy written by Johns Hopkins Medical Institutions is outlined and its implications discussed in this
article. The importance of such policies in guiding young faculty and staff as they begin their careers cannot be
overemphasized. (J Vasc Surg 2011;54:19S-21S.)
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PThe interaction between pharmaceutical and device
companies and physicians and hospitals has changed greatly
over the past 30 years since I began surgical training in
1980 and then began practicing as a vascular surgeon in
1987. There is proof that positive relationships with these
companies result in more use of the products and distribu-
tion to the public.1 This is thought to be due to our social
sense that the recipient of a gift will endeavor to reciprocate
even if they are not aware of this sense of indebtedness.
“Food, flattery, and friendship” are tactics that lead to
subtle acceptance of messages while in a pleasant social
environment.2 It has been found that physicians on average
have communication with pharmacy or device representa-
tives four times a month. This begins in medical school.3
The information exchanged in these interactions may not
always be correct or ethical. In a study by Stryer and Bero,
it was found that little of the material provided by the
pharmaceutical company to an academic internal medicine
residency program was more than just promotional, and
some failed to reside within Food and Drug Administration
(FDA) regulations.4
Patients do not feel that the relationship between phy-
sicians and pharmaceutical companies is something about
which they are concerned, and they trust their physician to
have their best interest at heart. In interviews of cancer
patients on clinical trials, 96% had complete trust in their
doctor, and 82% would have participated in the trial even if
the researcher had received speaking fees from the company
that made the drug in the trial. Yet, 62% thought there was
an oversight system in place to monitor financial ties of the
researchers.5
Many bioethics experts have called for a complete sep-
aration of physicians and other health care deliverers and
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doi:10.1016/j.jvs.2011.04.067he pharmaceutical and device companies. Moynihan feels
hat this entanglement is widespread and results in change
f practice and increased expense in the care of the pa-
ient.6-8 Strong believes that our culture needs to change so
hat physicians do not accept any gifts, whether the physi-
ian is in an academic health care system or in private
ractice.9
Many surgeons feel that their interaction with device
ompanies may be different than the interaction internal
edicine physicians have with pharmaceutical companies,
hich actually provide free samples and recommend alter-
ative medications for patients. Many surgeons feel that the
evice representatives are helpful while performing a pro-
edure because of the number of procedures the device
epresentative has seen performed by others. This expertise
s valuable, as is their ability to discuss devices and suggest
o the device representative ways to improve the device or
he procedure. In a study published by Korenstein and
ssociates, surgeons’ attitudes were more positive toward
ndustry than other specialty attending physicians – 75.8%
ersus 60.8%, (P  .001). Fewer surgeons believed that
ndustry should be prohibited from interacting with them;
0.9% versus 23.2%, (P  .001) or their trainees; 20.3%
ersus 32.9%, (P  .001). Surgeons were more likely to
pprove of industry to fund residency programs and to
ccept gifts, meals, and travel expenses as appropriate.10
ther surgeons have expressed concern about our interac-
ion with industry and feel that we need to be aware of our
ias and keep the lines distinct when industry is involved.11
The reputation of an academic medical center is main-
ained by the perception of the public as to the quality of
are delivered, the ease of access to the care, and the way in
hich the people who are delivering the care treat them or
heir loved ones as patients. Additionally, the public has
xpressed their concern about other aspects of our behav-
or, as we are the ones they entrust to provide them with the
ery best. These other aspects include the number of hours
e work, the amount of sleep we get, the use of alcohol or
ther drugs, and our relationship with the industry that not
nly provides devices, equipment, supplies, and medica-
ions for patients but may also provide incentives for the
hysician that potentially could influence our choices.
It was the purpose of the Johns Hopkins Medicine
olicy on the Interaction with Industry to preserve and
etain the trust of the public. The two objectives that were
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September Supplement 201120S Freischlagfelt to be essential were (1) to foster a culture where faculty,
staff, employees, and trainees have independent judgment
in all of their activities in order to deliver the best known
evidence-based and cost-effective medical care, and (2) to
allow, at the same time, appropriate interactions with industry
in order to develop new methods of treatment for their
patients, improving the overall health of the population at
large (http://www.hopkinsmedicine.org/Research/OPC/
Policy_Industry_Interaction/policy_interaction_industry.
html).
After much deliberation between all university constit-
uents, rather strict guidelines were developed and imple-
mented a year ago at Johns Hopkins Medicine. It was felt
by all that it was essential that the perception of our patients
and the public must be that we were engaged in only
appropriate and focused ways with industry from which we
do not stand to personally benefit. Therefore, gifts from
industry cannot be accepted by individuals with the excep-
tion of educational items such as books or posters. These
books and posters cannot have the logo of the company
displayed anywhere upon them. No meals or food can be
provided by industry unless it is for everyone at an Accred-
ited Council of Continuing Medical Education (ACCME)
function and is part of the program (ie, lunch provided
during an all-day course).
The most productive way for our academic leaders to
utilize their relationship with industry would be to accept
an unrestricted gift to their division or department. The
amount of this gift is under the sole discretion of the
division or department director. They are deposited into a
University account and can be used over time to support
faculty and staff education research and/or patient educa-
tion. Criteria should be established and well known by the
faculty members as to what kinds of activities can be sup-
ported by these resources. Additionally, any prizes or
awards for scientific or medical achievements can also be
placed in an individual’s account for use by the individual’s
own discretion.
Pharmaceutical samples cannot be accepted for distri-
bution in any office or clinic. The only exception would be
those needed for patient education use, such as inhalers.
Pharmaceutical assistance programs, vouchers, and large
retail chains with low cost medications are utilized instead.
As surgeons, site access such as the operating room for
pharmaceutical, medical testing, and other industry person-
nel is essential but needs to be regulated. Any other indi-
vidual outside of the Johns Hopkins faculty or staff who
needs to be in the operating room must be invited, and the
purpose of their presence should be clear. These individuals
can be essential to the success of an operation or procedure.
These individuals need to be appropriately credentialed,
and their presence needs to be disclosed to family and
patients. These individuals can give invited talks without
the use of any marketing materials if supervised by faculty.
These talks can be given at Grand Rounds, if appropriate,
and they are not patient-specific. Having such visits marked
on the calendar ensures the professional nature of such
visits. tMuch discussion was had about continuing medical
ducation (CME) at Johns Hopkins Medicine sites and the
se of the Johns Hopkins name or resources. It was decided
hat the Johns Hopkins University School of Medicine
ffice of Continuing Medical Education will be the sole
rovider of programs offering CME credit under the
ohns Hopkins name. These programs must comply with
CCME standards whether there is CME or not. Only mod-
st meals and social activities should accompany these pro-
rams to be accepted by Johns Hopkins Medicine attend-
es. If a Johns Hopkins faculty or staff member is speaking
or industry, they must have complete control of the con-
ent of the presentation. No Johns Hopkins faculty or staff
ember can be part of a speaker’s bureau. All payments
ust be disclosed. If a Johns Hopkins faculty or staff
ember attends an industry event, they must pay for their
wn meals. Any consulting for industry must be done at a
air market price with a written agreement in place. Indus-
ry can support lectures from faculty from their institutions
s long as the Johns Hopkins Medicine department con-
rols the choice of the speaker, the setting, who is invited,
nd the arrangements. Again, no marketing or promotional
ctivity can occur, and any such support from industry
eeds to be publically disclosed and acknowledged. Any
cholarship or other funds for trainees must be given to the
epartment or Division. The recipient is selected solely by
ohns Hopkins School of Medicine without any expecta-
ion from the industry source of the funds. The source can
e acknowledged. Any ghost writing by any Johns Hopkins
aculty or staff member is prohibited.
Purchasing of equipment has to be made based solely
pon medical decisions and not upon any financial interest
n the company. If there is any financial interest in the
ompany, it must be disclosed. And, if there is financial
nterest in the company, this must have terminated 1 year
rior to any purchase from that company.
One of the other reasons that disclosure of any relation-
hip with industry is so important is to aid in guiding the
oung faculty and staff who may develop relationships with
ndustry that absorb their time and prevent them from
ngaging in more important academic activities. This can
esult in conflict of commitment. These reports are essential
or chairs of departments to ensure faculty remains on track
n their academic career. The Johns Hopkins University
olicy on Conflict of Commitment helps to provide a
ramework for these activities so they can be monitored.
Sanctions for those who do not comply with the policy
n interaction with industry do exist. For a single event, the
hief or director will meet with the individual and remind
hem of their obligations to comply with the policy. If there
re repeated or deliberate episodes of failure to comply,
hese events will be reviewed by the chief or director and
ill be reviewed by the Johns Hopkins Medicine Commit-
ee on Professional Misconduct.
Since the introduction of the Physician Payments Sun-
hine Act in 2007 by Senators Charles Grassley (R-IA) and
erb Kohn (D-WI), much more attention has been paid tohe development of policies in academic health care centers
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icy, as I have outlined, is one such good one, but many exist
at other institutions as well.
I do believe that healthy relationships can exist between
pharmaceutical and device companies that will result in
better care of the patient and the development of new
drugs, devices, and procedures.13 We just need to be clear –
crystal clear – to the public, and ourselves, just what that
relationship is.
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